ICN Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of SLS Biophile Ltd. and its laser-based, non-ablative wrinkle reduction technology is announced June 28, expanding the drug firm's dermatological franchise. A March 510(k) application is pending at FDA for Swansea, Wales-based SLS Biophile's N-Lite laser treatment system, which has been available in Europe since early this year as an alternative to chemical-based treatments. Financial terms of the deal were not disclosed